Ideaya Expands its 2020 Collaboration and Supply Agreements with Pfizer for Darovasertib + Crizotinib to Treat Metastatic Uveal Melanoma and cMET-Driven Tumors
Shots:
- The companies collaborated to support darovasertib (PKC inhibitor) + crizotinib (cMET inhibitor) in the P-II registration-enabling trial in patients with MUM & P-I trial for cMET-driven tumors including HCC & NSCLC
- In the preliminary studies, darovasertib + crizotinib for MUM showed robust clinical activity with a manageable side effect profile while the clinical efficacy provides PoC in other cMET-driven tumors
- The P-I/II trial updates of darovasertib + crizotinib in MUM are expected in mid-2022 including tolerability & clinical efficacy. The company also plans for the US FDA regulatory guidance to evaluate the combination therapy in registration-enabling trial for MUM in mid-2022
Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
